1 Title:

- 2 Islet autoantibody level distributions in type 1 diabetes and their association with genetic and
- 3 clinical characteristics

4 Authors:

- 5 Sian Louise Grace¹, Jack Bowden¹, Helen C. Walkey², Akaal Kaur², Shivani Misra²,
- 6 Beverley M. Shields¹, Trevelyan J. McKinley¹, Nick S, Oliver², Timothy McDonald^{1,3},
- 7 Desmond G. Johnston², Angus G. Jones^{1,4}, Kashyap Amratial Patel^{1,4}

8 Author affiliations:

- 9 ¹The Institute of Biomedical & Clinical Science, University of Exeter Medical School,
- 10 Exeter, U.K.
- ²Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London,
 U.K.
- ³Academic Department of Clinical Biochemistry, Royal Devon and Exeter NHS Foundation
 Trust, Exeter, U.K.
- ⁴Macleod Diabetes and Endocrine Centre, Royal Devon and Exeter NHS Foundation Trust,
- 16 Exeter, U.K.

17 Corresponding author:

- 18 Dr Kashyap A. Patel; Level 3 RILD Building, RD&E Wonford, Barrack Road, Exeter,
- 19 Devon, EX2 5DW. K.A.Patel@exeter.ac.uk, Tel: +44 1392 408237
- 20 Word count: 3493
- 21 Number of tables and figures: 2 x Figures & 2 x Tables
- 22 Electronic Supplemental Material: 2 x Figures & 5 x Tables

23 Abstract

24 Positivity for islet autoantibodies is used for diagnosis of type 1 diabetes. However, the 25 importance of the autoantibody level at diagnosis of type 1 diabetes is not clear. Here, we 26 assessed the association of glutamate decarboxylase (GADA), islet antigen-2 (IA-2A) and 27 zinc transporter 8 (ZnT8A) autoantibody levels, measured using radiobinding assays, on genetic and clinical characteristics at diagnosis of 1536 participants with diabetes who were 28 29 positive for these autoantibodies. We show that GADA and IA-2A levels had bimodal 30 distributions, but ZnT8A level did not. The comparison of genetic and clinical characteristics 31 between high and low level categories showed high GADA level was associated with older 32 age at diagnosis, female sex and HLA-DR3-DQ2, whereas high IA-2A level was associated 33 with younger age of diagnosis, ZnT8A positivity and HLA-DR4-DQ8. We replicated our 34 findings in an independent cohort of 427 people with type 1 diabetes where autoantibodies 35 were measured using enzyme-linked immunosorbent assays. In conclusion, Islet autoantibody 36 levels provide additional information over positivity in type 1 diabetes at diagnosis. The 37 bimodality of islet autoantibody levels highlights the novel aspect of heterogeneity of type 1 diabetes which may have implications on prediction, treatment and prognosis. 38

39

41 Islet autoantibodies are commonly used in the diagnosis and prediction of type 1 diabetes. 42 They are well established as the biomarkers of the underlying autoimmune pathogenesis (1). 43 Autoantibodies to islet cell antigen (ICA), glutamate decarboxylase (GADA), islet antigen-2 44 (IA-2A), insulin (IAA) and zinc transporter 8 (ZnT8A) are the most commonly used islet 45 autoantibodies at diagnosis (2). As detectable islet autoantibodies overlap between health and 46 disease, a test is usually considered positive for a given islet autoantibody when the antibody level is higher than a 97.5–99th centile of a control population (3; 4). In routine clinical 47 48 practice, quantitative islet autoantibody results are usually interpreted as positive or negative, 49 and the level of the islet autoantibody, is not thought to be clinically meaningful.

50 Islet autoantibody levels may provide additional information over positivity in type 1 diabetes 51 at diagnosis. Similar to type 1 diabetes, autoantibodies to a specific antigen are commonly 52 used for diagnosis in many other autoimmune diseases (such as TSH receptor antibodies in 53 Graves' disease and Rheumatoid Factor and Citrullinated Protein in rheumatoid arthritis). For 54 Graves' disease and rheumatoid arthritis, along with autoantibody positivity for these 55 antigens, autoantibody level at diagnosis is associated with disease severity, prognosis and 56 treatment success (5; 6). Multiple studies have shown a role for islet autoantibody level in the 57 prediction of onset of type 1 diabetes, those with a higher levels of IA-2A, IAA and ICA have 58 an increased risk of developing type 1 diabetes in at-risk populations (1; 7-9). However, it is 59 not clear if the islet autoantibody level at diagnosis of type 1 diabetes, in addition to its interpretation as 'positive', is associated with the clinical phenotype similar to other 60 61 autoimmune diseases.

In this study, we undertook an analysis of GADA, IA-2A and ZnT8A levels at diagnosis in a large cohort of participants with type 1 diabetes, assessing the association of islet autoantibody levels on genetic and clinical characteristics at diagnosis in people with type 1 diabetes.

66

67 Research Design and Methods

68 <u>Study cohorts</u>

69 We recruited 1536 participants with a clinician-assigned diagnosis of type 1 diabetes (age at 70 diagnosis range 4-74 years) who were positive for any of GADA, IA-2A or ZnT8A at 71 diagnosis. These participants were recruited as part of the UK-wide ADDRESS-2 study. The 72 detailed protocol for the study has been published previously (10). The included participants 73 were recruited at diagnosis (<6 months), were >4y of age, insulin-treated from diagnosis, and were self-reported to be of white European ethnicity. We excluded individuals with non-74 75 European ethnicity as the type 1 diabetes genetic risk score is only validated for those with 76 European ancestry. DNA and serum samples, clinical data (including the characteristics of 77 diabetes at diagnosis) were collected at recruitment. The overall cohort characteristics are 78 provided in ESM Table 1.

We used a second independent replication cohort of 427 participants with clinically diagnosed type 1 diabetes (age at diagnosis range 17–81 years) and positivity to any of the three islet autoantibodies (GADA, IA-2A and ZnT8A). The participants were part of the UKwide StartRight study (11). All were recruited <12 months from diagnosis, insulin-treated from diagnosis and self-reported to be of white European ethnicity. The overall cohort characteristics is provided in ESM Table 1.

85 Islet autoantibody measurement

ADDRESS-2 study: The islet autoantibodies (GADA, IA-2A and ZnT8A) were measured
using established radiobinding assays by the Diabetes and Metabolism group at the
University of Bristol (Bristol, U.K.) (12; 13) at a median of 10.1 weeks diabetes duration.
Results for GADA and IA-2A are expressed in digestive and kidney units/mL (DK units/mL)

90 units/mL or arbitrary units (AU/mL) for ZnT8A calculated from standard curves consisting of 91 diluted patient sera in antibody-negative sera from healthy donors. Positive thresholds were 92 set at 97.5th percentile of 974 control samples for GADA (\geq 33 DK U/ml), the 98th percentile 93 of 500 control samples for IA-2A (\geq 1.4 DK U/ml) and the 97.5th percentile of 523 healthy 94 school children for ZnT8A (\geq 1.8 AU/ml) (14). The laboratory participates in the Islet 95 Autoantibody Standardisation Program (IASP) (ESM Table 2).

96 StartRight study: GADA, IA-2A and ZnT8A islet autoantibodies were measured using 97 ELISA assays (RSR Limited, Cardiff, U.K.) on a Dynex DS2 automated ELISA system 98 (Launch Diagnostics, Longfield, U.K.), at a median of 14.9 weeks diabetes duration by the Academic Department of Blood Sciences, Royal Devon and Exeter Hospital (Exeter, U.K.) 99 (15). Positive thresholds were set at the 97.5th percentile of 1559 non-diabetic control subjects 100 101 (GAD \geq 11 WHO (World Health Organization) U/mL, IA-2 \geq 7.5 WHO U/mL, ZnT8 age \geq 102 30 years \geq 10 U/mL, ZnT8 age < 30 years \geq 65 U/mL). Upper reporting limits for GADA, 103 IA-2A and ZnT8A were 2000 WHO U/mL, 4000 WHO U/mL and 2000 U/mL respectively. 104 The laboratory also participates in IASP (ESM Table 2) (16).

105 *Type 1 diabetes genetic risk score and HLA genotypes*

106 We generated weighted T1D-GRS from 30 common type 1 diabetes genetic variants (single

107 nucleotide polymorphisms [SNPs]) for HLA and non-HLA loci as described in our previous

- 108 papers (17). HLA DR3-DQ2 and HLA-DR4-DQ8 were imputed from two SNPs as described
- 109 in our previous paper (15).

110 <u>Statistical Analysis</u>

We used histograms to assess the distribution of islet autoantibody levels in those positive for that autoantibody. Autoantibody levels with bimodal distributions were split into high or low level categories using the nadir (lowest point between distributions). We also used a normal

mixture model analysis and likelihood ratio tests to assess whether uni-modal, bi-modal or multi-modal distributions were best supported by the data. This analysis was performed on log-transformed autoantibody level data so that it was better approximated by a mixture of continuous, symmetric normal distributions. This was implemented using the mixtools package in R (18).

We performed Mann-Whitney tests to compare the continuous variables and Pearson chisquare tests were used to compare categorical variables between autoantibody level categories. All statistical analysis was carried out using Stata/SE 16.0 (StataCorp, College Station, TX) unless otherwise stated.

123 **Results**

GAD and IA-2 but not ZnT8 autoantibody levels exhibit a bimodal distribution at diagnosis in type 1 diabetes

126 We first assessed the distribution of GADA level in GADA positive type 1 diabetes people 127 (n=1268), IA-2A level in IA-2A positive type 1 diabetes people (n=1034), and ZnT8A level 128 in ZnT8A positive type 1 diabetes people (n=906). The distribution of the GADA and IA-2A 129 levels showed two peaks consistent with a bimodal distribution (Fig. 1A & 1B). ZnT8A level 130 showed a single peak with right-skewed distribution (Fig. 1C). Bimodality of GADA and IA-131 2A levels was also confirmed using a mixture model analysis (ESM Fig. 1A & 1B). 132 Specifically, we analysed IA-2A and GADA levels on the log scale and used a likelihood 133 ratio test (LRT) on 3 degrees of freedom to compare the log-likelihood of a one-component 134 normal distribution with two parameters (one mean and one variance) versus that of a two-135 component, five parameter normal mixture (two means, two variances and a weight 136 determining the relative proportion of each component). Under the null hypothesis that the 137 single normal distribution was the true data generating model, twice the difference in log-138 likelihoods between the one-component and two-component models (referred to as the LRT)

139 follows a chi-squared distribution on 5-2 = 3 degrees of freedom. Both analyses yielded overwhelming evidence in favour of the two-component model (LRT_{IA-2A} = 1129, p<2x10⁻¹⁶, 140 LRT_{GADA}= 345, p<2x10⁻¹⁶). We used the nadir value between the two peaks to divide the 141 bimodal distribution of the autoantibody levels into two groups (low vs. high levels) for the 142 143 subsequent analysis. The nadir value for GADA levels was 452 DK U/ml. All participants 144 with a GADA level lower than this value were grouped into a low level GADA group (mean 145 level 180.3, SD +/-118.4, 711/1268 (56%)) and the participants with a GADA level above or 146 equal this value were grouped into a high level GADA group (760.9, +/-229.3, 557/1268 147 (44%)). Similarly, the nadir value of 130 DK U/ml between the two peaks of IA-2A levels 148 divided people into a low level IA-2A group (mean level 41.2, SD+/-37.4, 285/1034 (28%)) 149 and a high level IA-2A group (301.0, +/-88.3, 749/1034 (72%)).

Higher GADA levels were associated with later age at diagnosis of type 1 diabetes, female sex, and *HLA-DR3-DQ2*.

152 To assess the association of bimodal GADA levels to clinical features at diagnosis, we compared the clinical features between the people with low level (lower mode) and high level 153 154 (higher mode) GADA as defined above (Table 1). Those in the high level GADA group were 155 diagnosed later compared to the low GADA level group (median 27.1 y [IQR 17.5-38.8] vs. 19.4 y [12.9-29.7], P=3x10⁻¹⁶) (Fig. 2) (Table 1). They were more likely to be female (52% 156 vs. 36%, $P=1\times10^{-8}$), and more likely to have other autoimmune diseases (13% vs. 5%, 157 $P=5x10^{-6}$) compared to low level GADA group (Table 1). They had modest enrichment for 158 *HLA DR3-DQ2* (59% vs. 50%, $P=3x10^{-3}$) but had similar T1D-GRS (median 0.275 [IQR 159 0.256-0.293] vs. 0.274 [0.253-0.292], P=0.53) based on 30 T1D associated common variants 160 161 (19). The presentation characteristics (DKA, weight loss, polyuria, HbA1c and BMI), the 162 number of other islet autoantibodies and other islet autoantibody levels were similar between 163 the two GADA level groups.

164 Higher IA-2A levels were associated with earlier age at diagnosis of type 1 diabetes and

165 HLA DR4-DQ8 and ZnT8A positivity.

166 We next compared the clinical features of low and high IA-2A level groups to assess 167 association of bimodal IA-2A level distribution to clinical features at diagnosis. (Table 2). Contrary to GADA, those in the higher level IA-2A group were diagnosed earlier compared 168 169 to the lower IA-2A level group (median 17.0 years [IQR 11.9-25.2 years] vs. 22.4 years [13.1-33.5 years], $P=4x10^{-6}$) (Fig. 2) (Table 2). They were more likely to be multiple 170 autoantibody positive (60% vs. 42% with three autoantibodies, $P=1\times10^{-9}$), positive for 171 ZnT8A (78% vs. 52%, $P=2x10^{-16}$) and more likely to have higher ZnT8A levels (median 172 level 44 AU/ml [IQR 16-86] vs. 26 [7.7-55]) ($P = 1 \times 10^{-5}$). Those with higher IA-2A levels 173 174 were more likely to have HLA DR4-DQ8 (68% vs. 51%, $P=5\times10^{-7}$). The presentation 175 characteristics were similar between IA-2A level groups (Sex, DKA, weight loss, polyuria, 176 HbA1c and BMI, parent with diabetes) (Table 2).

177 ZnT8A level at diagnosis was not associated with age at diagnosis of type 1 diabetes

178 To assess the association of ZnT8A level to clinical features at diagnosis, we divided 906 179 T1D cases who were positive for ZnT8A by the median value of the distribution (35.4 180 AU/ml) due to lack of clear bimodal distribution. No statistically or clinically significant 181 relationship was found between ZnT8A level and age at diagnosis (19.0 years [12.3-30.1] vs. 17.4 [12.2, 26.4], p=0.07) (Fig. 2) or HLA DR3-DQ2 or DR4-DQ8. Both groups also 182 exhibited similar presentation characteristics (DKA, weight loss, polyuria, HbA1c and BMI). 183 184 However, those with higher level ZnT8A were more likely to be multiple autoantibody 185 positive (71% vs. 55% with three autoantibodies) and more likely to be positive for IA-2A 186 (86% vs. 76% $P=1.5 \times 10^{-4}$) (ESM Table 3) and GADA (83% vs. 74% P=0.002). Similar 187 results for the lack of association of ZnT8A level to age at diagnosis were observed with

linear regression analysis of log ZnT8A level to age at diagnosis (β =-0.57, 95% CI -1.2,0.08,

189 *P*=0.09).

Bimodal distributions of GAD and IA-2 islet autoantibody levels were also observed in second independent cohort

192 To replicate our results with different assay and different cohort, we analysed GADA, IA-2A

and ZnT8A levels in 427 patients with type 1 diabetes at diagnosis from the StartRight study

where islet autoantibody levels were measured using ELISA assays; another commonly usedassay for islet autoantibody measurement.

Similar to our primary cohort, GADA and IA-2A levels showed a bimodal distribution in this replication cohort, with ZnT8A showing one peak with right skewed distribution (ESM Figure 2). The shape of the distribution is different in this cohort due to the clinical laboratory conducting the ELISAs not reporting results that are outside the standard curve leading to truncation at higher levels.

201 Using the same method as our primary cohort, we divided the GADA and IA-2A bimodal 202 distributions into high and low autoantibody level groups using the nadir between the peaks 203 (ESM Figure 2). Similarly to our primary analysis, those in the high level GADA group were 204 diagnosed later compared to the low GADA level group (41 years [IQR 32-53 years] vs. 30 years [IOR 24-38 years], $P=7\times10^{-13}$), were more likely to be female (61% vs. 42%, $P=2\times10^{-4}$) 205 206 and were more likely to have a concurrent autoimmune disease (22% vs. 11%, $P=2x10^{-3}$) 207 (ESM table 4). There were no differences in presentation characteristics, parent with diabetes, 208 or C-peptide (ESM Table 4). The participants with higher IA-2A levels were younger 209 (median 29 years vs. 33 years) compared to the ones with lower IA-2A levels, as our primary 210 cohort, but this difference was not statistically significant (ESM Table 5).

212 Discussion

Our study shows that GADA and IA-2A level at diagnosis of type 1 diabetes show clear bimodal distributions. Dichotomising levels into high or low groups according to the observed modes exhibits strong associations with age at diagnosis of type 1 diabetes but not with severity of type 1 diabetes at diagnosis.

217 There have been multiple studies of islet autoantibody levels in at-risk populations for type 1 218 diabetes (1; 7-9) and within type 1 diabetes populations but none of the studies to our 219 knowledge have suggested that GADA and IA-2A have a bimodal distribution of level. 220 However, the bimodality of GADA levels but not IA-2A levels has been reported in people 221 with latent autoimmune diabetes (LADA) (20; 21). We were able to show the bimodality of 222 levels using a second independent cohort of people with type 1 diabetes as well as using a 223 second method for measuring islet autoantibodies. These data suggest that the bimodality of 224 GADA and IA-2A levels is likely to be a true biological phenomenon, rather than an assay 225 artefact, that is observed at diagnosis of type 1 diabetes.

226 The underlying biology of bimodality of GADA and IA-2A levels is not known and will need 227 further investigation. We observed an enrichment of HLA DR3-DQ2 and HLA DR4-DQ8 in 228 people with higher GADA levels and IA-2A levels respectively. Both these associations are 229 well-described with the positivity of the respective autoantibodies but not with the 230 autoantibody levels (22; 23). The difference in HLA susceptibility suggests a role for 231 humoral immunity and antigen recognition as one of the factors underlying bimodality. 232 However, the association with HLA was modest in our study and the overall genetic risk 233 score was similar with high and low autoantibody level groups suggesting that there are 234 additional factors which are responsible for the observed bimodality. Previous studies have 235 shown that high GADA levels are correlated with higher affinity autoantibodies, the central

and c-terminal epitopes, and multiple autoantibodies positivity (24). We did not observe the association of high GADA level with multiple autoantibodies, but we did observe the association of higher IA-2A level with multiple autoantibodies. These data suggest that affinity, the difference in epitopes, and the presence of other autoantibodies may also contribute towards bimodality.

241 GADA and IA-2A levels are associated with age at onset but in opposite directions. The 242 participants who had high GADA levels were nearly 7 years older at diagnosis compared to 243 the ones with low level GADA. This was replicated in a second independent cohort of adults 244 with type 1 diabetes. Contrary to GADA, participants with high IA-2A levels were 5.4 years 245 younger at diagnosis compared to those with low IA-2A levels. Interestingly, we note that 246 both GADA and IA-2A levels but not ZnT8A level follows the same association with age as 247 positivity of these autoantibodies (14; 25; 26). It has been shown that the pattern of positive 248 autoantibody changes with age. The older-onset type 1 diabetes have a higher proportion of 249 GADA whereas childhood-onset diabetes has a higher proportion of IA-2A, IAA and ZnT8A. 250 The underlying reason for this observation is not clear. However, it is not due to change in 251 overall humoral immunity due to age as we see the opposite effect of autoantibody levels on 252 age with different autoantibodies. In contrast to our findings in type 1 diabetes, studies of 253 LADA have shown that higher GADA level is associated with early age of onset. This may 254 relate to the very different populations studied and the relationship between age and prior prevalence of autoimmune diabetes which, as recently suggested, may markedly alter 255 256 antibody false positive rates in populations of apparent type 2 diabetes (21; 26). Studies of 257 the at-risk population have shown higher IA-2A level is associated with earlier age of onset 258 of type 1 diabetes supporting our observation of an inverse relationship between IA-2A level 259 and age (27; 28). In contrast, studies of at-risk individuals have not reported an association of

GADA level with the age of onset of type 1 diabetes (1; 28). The lack of inclusion of adults and focus on children in these studies may explain the lack of association.

262 We show that despite greatly different autoantibody levels, autoantibody level at diagnosis 263 was not strongly associated with severity of presentation of type 1 diabetes as reflected by 264 symptoms of hyperglycaemia, proportions with DKA, osmotic symptoms and weight loss, as 265 well as C-peptide and HbA1c at diagnosis. These results contrast previous studies in LADA 266 where high levels of GADA were associated with lower BMI, C-peptide and higher HbA1c 267 (21). In contrast to LADA, higher levels of ICA but not GADA and IA-2A at diagnosis of 268 type 1 diabetes was associated with C-peptide <50 pmol at 2 years (29). In a recent cross-269 sectional study of patients with type 1 diabetes; high GADA levels, but not IA-2A and 270 ZnT8A levels, were individually associated with lower c-peptide (<2.5 pmol). However, in 271 this study islet autoantibodies were measured at median 7.5 years after diagnosis and 272 association of GADA levels were only seen at 2.1 years (30). Further longitudinal studies are 273 needed to assess the association of bimodality of autoantibody level at diagnosis with beta-274 cell function over time in type 1 diabetes.

275 Our findings have important implications for the prediction, treatment and prognosis of type 276 1 diabetes. It is well known that type 1 diabetes is a heterogeneous disease with heterogeneity 277 in islet autoantibodies, beta-cell function, genetics as well as response to immunomodulatory 278 therapy (31). The research to date mainly focuses on the positivity of autoantibodies rather 279 than autoantibody levels in type 1 diabetes. We believe that autoantibody levels showing a 280 bimodality for GADA and IA-2A is an important consideration in understanding the 281 heterogeneity of type 1 diabetes. It is well known that immunomodulatory therapy has a 282 variable response on beta-cell function in clinical trials (32). Currently, the reason for this 283 variable response is not entirely known but is proposed to be due to variation in T cell 284 response (33; 34). The bimodality of the levels may represent a surrogate marker of a specific

immune response and identify the subgroup of individuals with differential response to immunomodulatory therapy but this needs testing in further studies. This, along with the association of GADA level with c-peptide in a recent study, provides an exciting possibility of a stratified approach to type 1 diabetes treatment and prognosis which is currently lacking (30). Our findings also make a strong case to assess the usefulness of the bimodality of GADA and IA-2A levels in the prediction models of progression of diabetes in at-risk population in addition to autoantibody positivity.

292 Our autoantibody levels were assessed using radiobinding assays in our primary cohort. We 293 did not measure autoantibody levels by ELISA on the same cohort to validate our findings 294 using this more-commonly used assay in routine clinical laboratories. However, we observed 295 similar results with ELISA assay in the second cohort; both laboratories participate in IASP 296 and a high correlation of levels between the ELISA and radiobinding assay (35; 36) meaning 297 that our findings are applicable to levels measured by both methods. Although a bimodal 298 distribution of GADA and IA-2A was observed using both assay methods, the shape of the 299 distributions does look different between assays. We believe this is due to the clinical 300 laboratory conducting the ELISAs not reporting results that are outside the standard curve 301 causing truncation at both ends in comparison the RBA laboratory which reports extrapolated 302 results.

Our study is limited to white-European populations, due to lack of validity of T1D GRS in non-European ethnicity and further studies are needed in non-white ethnicity. Also, we only had c-peptide information at diagnosis and only in one of the study cohorts, therefore we are limited in our ability to assess the impact of autoantibody level distribution on beta cell function. We did not study insulin autoantibodies (IAA) as this would not be appropriate due to the nature of our cohorts being recruited weeks after diagnosis of type 1 diabetes and commencement of insulin therapy.

In conclusion, we show that GADA and IA-2A levels exhibit a bimodal distribution at diagnosis of type 1 diabetes, which is biologically important to the understanding of the heterogeneity of type 1 diabetes and opens the exciting possibility of further research to assess its implication on prediction, treatment and prognosis of type 1 diabetes.

314 Article Information

315 Acknowledgements

The authors acknowledge the staff of the Diabetes and Metabolism Group (University of Bristol) and of the Academic Department of Biochemistry (Royal Devon and Exeter NHS Trust) for their role in collecting the autoantibody data. K.A.P is the guarantor of this work and, as such, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Finally, the authors would like to thank all the participants of the ADDRESS-2 and StartRight studies.

322 Author Contributions

323 S.L.G assayed the Address-2 autoantibody samples at Bristol, researched the data and wrote 324 the manuscript. S.L.G, K.A.P and J.B researched the data and wrote the manuscript. A.G.J 325 and T.J.McD helped plan the research, contributed to the discussion and reviewed/edited the 326 manuscript. B.M.S and T.J.McK contributed to data analysis and reviewed/edited the 327 manuscript. A.G.J set up the study from which the replication cohort was selected. H.C.W, 328 A.K, S.M, N.S.O and D.G.J. set up the ADDRESS-2 study from which the original cohort 329 was selected, collected the clinical data and reviewed/edited the manuscript. This work, in 330 part, has been presented as a poster at the nPOD conference (2021) and the Diabetes UK 331 Professional Conference (2021).

332 Funding

S.L.G is supported by a PhD Studentship funded by an Expanding Excellence in England(E3) award from Research England. K.A.P has a Career Development fellowship funded by

- the Wellcome Trust (219606/Z/19/Z). A.G.J was supported by an NIHR Clinician Scientist
- award (CS-2015-15-018). T.J.McD is a National Institute for Health Research Senior Clinical
- 337 Senior Lecturer. JB and T.J.McK are funded by an Expanding Excellence in England (E3)
- 338 research grant to the University of Exeter. S.M is a recipient of the Future Leaders
- 339 Mentorship award from the European Federation for the Study of Diabetes. D.G.J, S.M and
- 340 N.S.O are supported by the National Institute for Health Research (NIHR) Biomedical
- 341 Research Centre based at Imperial College London. The views given in this article do not
- necessarily represent those of the National Institute for Health Research, The National Health
- 343 Service, the Department of Health and Social Care, or Research England.

344 **Duality of Interest**

No potential conflicts of interest relevant to this article were reported.

346 **References**

- 1. Achenbach PW, K.; Reiter, J.; Naserke, H.E.; Williams, A.J.K.; Bingley, P.J.; Bonifacio,
- E.; Ziegler, A-G.: Stratificiation of Type 1 Diabetes Risk on the Basis of Islet Autoantibody
- Characteristics. Diabetes 2004;53:384-392
- 2. Bingley PJ, Williams AJ: Islet autoantibody testing: an end to the trials and tribulations?
- 351 Diabetes 2013;62:4009-4011
- 352 3. Bingley PJ: Clinical applications of diabetes antibody testing. The Journal of clinical
 and applications 2010;95:25-33
- 4. Schlosser M, Strebelow M, Rjasanowski I, Kerner W, Wassmuth R, Ziegler M: Prevalence
- of Diabetes-Associated Autoantibodies in Schoolchildren: The Karlsburg Type 1 Diabetes
- Risk Study. Annals of the New York Academy of Sciences 2004;1037:114-117
- 5. de Brito Rocha S, Baldo DC, Andrade LEC: Clinical and pathophysiologic relevance of
 autoantibodies in rheumatoid arthritis. Advances in Rheumatology 2019;59:2
- 6. Hesarghatta Shyamasunder A, Abraham P: Measuring TSH receptor antibody to influence
 treatment choices in Graves' disease. Clinical Endocrinology 2017;86:652-657
- 361 7. Steck AK, Dong F, Waugh K, Frohnert BI, Yu L, Norris JM, Rewers MJ: Predictors of
 362 slow progression to diabetes in children with multiple islet autoantibodies. Journal of
 363 Autoimmunity 2016;72:113-117
- 8. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC,
- Rafkin L, Schatz D, Eisenbarth G: The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives
- 367 of Type 1 Diabetic Patients. Diabetes Care 2013;36:2615
- 368 9. Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EA, Bottazzo GF:
- 369 Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet
- 370 1990;335:147-149

371 10. Walkey HC, Kaur A, Bravis V, Godsland IF, Misra S, Williams AJK, Bingley PJ, Dunger 372 DB, Oliver N, Johnston DG: Rationale and protocol for the After Diabetes Diagnosis 373 REsearch Support System (ADDRESS): an incident and high risk type 1 diabetes UK cohort 374 study. BMJ Open 2017;7:e013956 375 11. Clinicaltrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). 2000 376 Feb 29 - StartRight: Getting the Right Classification and Treatment From Diagnosis in Adults 377 With Diabetes; 2016. Available from: https://ClinicalTrials.gov/show/NCT03737799. 378 12. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K, 379 Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization 380 of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute 381 of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 382 2010;95:3360-3367 383 13. Long AE, Gooneratne AT, Rokni S, Williams AJK, Bingley PJ: The Role of 384 Autoantibodies to Zinc Transporter 8 in Prediction of Type 1 Diabetes in Relatives: Lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Cohort. The Journal of 385 386 Clinical Endocrinology & Metabolism 2012;97:632-637 387 14. Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, Williams AJK, Dunger 388 DB, Dayan CM, Peakman M, Oliver NS, Johnston DG, Address-2 Management Committee 389 PAG, Investigators: Relationship between islet autoantibody status and the clinical 390 characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open 391 2018;8:e020904 392 15. Thomas NJ, Lynam AL, Hill AV, Weedon MN, Shields BM, Oram RA, McDonald TJ, 393 Hattersley AT, Jones AG: Type 1 diabetes defined by severe insulin deficiency occurs after 394 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 2019;62:1167-1172 395 16. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P, Williams A, 396 Hattersley AT, Ellard S: Islet autoantibodies can discriminate maturity-onset diabetes of the 397 young (MODY) from Type 1 diabetes. Diabetic Medicine 2011;28:1028-1033 398 17. Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, Hattersley AT, Weedon 399 MN: A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and 400 Type 2 Diabetes in Young Adults. Diabetes Care 2016;39:337

- 401 18. Benaglia T, Chauveau D, Hunter DR, Young DS: mixtools: An R Package for Analyzing 402 Mixture Models. Journal of Statistical Software; Vol 1, Issue 6 (2010) 2009;
- 403 19. Patel KA, Oram RA, Flanagan SE, De Franco E, Colclough K, Shepherd M, Ellard S, 404 Weedon MN, Hattersley AT: Type 1 Diabetes Genetic Risk Score: A Novel Tool to 405 Discriminate Monogenic and Type 1 Diabetes. Diabetes 2016;65:2094-2099
- 406 20. Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, Yang L, Lin J, Liu Z, Hagopian WA,
- 407 Leslie RD: Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune 408
- Diabetes in China (LADA China Study). Diabetes 2013;62:543
- 409 21. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi
- 410 ML, Bazzigaluppi E, Dotta F, Bosi E: High titer of autoantibodies to GAD identifies a 411 specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30:932-938
- 412 22. Wenzlau JM, Frisch LM, Hutton JC, Fain PR, Davidson HW: Changes in Zinc 413 Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes 414 Genetics Consortium Autoantibody Workshop. Diabetes Care 2015;38 Suppl 2:S14-20
- 415 23. Hagopian WA, Sanjeevi CB, Kockum I, Landin-Olsson M, Karlsen AE, Sundkvist G,
- 416 Dahlquist G, Palmer J, Lernmark A: Glutamate decarboxylase-, insulin-, and islet cell-
- 417 antibodies and HLA typing to detect diabetes in a general population-based study of Swedish
- 418 children. The Journal of Clinical Investigation 1995;95:1505-1511

- 419 24. Mayr A, Schlosser M, Grober N, Kenk H, Ziegler AG, Bonifacio E, Achenbach P: GAD
 420 Autoantibody Affinity and Epitope Specificity Identify Distinct Immunization Profiles in
- 421 Children at Risk for Type 1 Diabetes. Diabetes 2007;56:1527
- 422 25. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, Schaefer JB,
- 423 Zarghami M, Day HL, Landin-Olsson M, Palmer JP, Janer-Villanueva M, Hood L, Sundkvist
- 424 G, Lernmark Å, Breslow N, Dahlquist G, Blohmé G: Genetic Effects on Age-Dependent
- 425 Onset and Islet Cell Autoantibody Markers in Type 1 Diabetes. Diabetes 2002;51:1346
- 426 26. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M:
- Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1
 diabetes. Diabetes Care 2000;23:1326-1332
- 429 27. Mrena S, Virtanen SM, Laippala P, Kulmala P, Hannila M-L, Åkerblom HK, Knip M:
 430 Models for Predicting Type 1 Diabetes in Siblings of Affected Children. Diabetes Care
 431 2006;29:662
- 432 28. Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, Eisenbarth GS, Rewers MJ:
- 433 Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2
- Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes. Diabetes Care 2011;34:1397
- 29. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C, Rottiers R,
 Winnock F, ver Elst K, Weets I, Kaufman L, Pipeleers DG, Rottiers R: Use of an islet cell
 antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels
- 438 after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000;23:1072
- 30. Williams MD, Bacher R, Perry DJ, Grace CR, McGrail KM, Posgai AL, Muir A,
 Chamala S, Haller MJ, Schatz DA, Brusko TM, Atkinson MA, Wasserfall CH: Genetic
- 441 Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide
 442 Following Type 1 Diabetes Diagnosis. Diabetes 2021:db200937
- 443 31. Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M: The challenge of
- 444 modulating β -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 2019;7:52-64 445 32. Warshauer JT, Bluestone JA, Anderson MS: New Frontiers in the Treatment of Type 1
- 446 Diabetes. Cell Metabolism 2020;31:46-61
- 447 33. Eichmann M, Baptista R, Ellis RJ, Heck S, Peakman M, Beam CA: Costimulation
- 448 Blockade Disrupts CD4<sup>+</sup> T Cell Memory Pathways and Uncouples 449 Their Link to Decline in β -Cell Function in Type 1 Diabetes. The Journal of Immunology
- 450 2020;204:3129
- 451 34. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA,
- 452 Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA,
- 453 Schatz DA: Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained
- 454 Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type
- 455 1 Diabetes. Diabetes 2016;65:3765
- 456 35. Takagi S, Miura J, Hoshina S, Uchigata Y, Babazono T: Clinical and genetic 457 characteristics of people with type 1 diabetes who have discrepancies in titers of anti-458 glutamic acid decarboxylase antibody measured by radioimmunoassay and enzyme-linked 459 immunosorbent assay. Journal of Diabetes Investigation 2020;11:356-362
- 460 36. Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J,
- Rewers M, Yu L: Electrochemiluminescence Assays for Insulin and Glutamic Acid
 Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk. Diabetes
- 463 Technology & Therapeutics 2015;17:119-127

Characteristic	Low Level GADA	High Level GADA	P value
n (%)	711 (56)	557 (44)	
GADA level (DK U/ml)	147 (75, 277)	719 (592, 866)	
Female (%)	259 (36)	292 (52)	$1 \times 10^{-8} *$
Age of Diagnosis (years)	19.4 (12.9, 29.7)	27.1 (17.5, 38.8)	$3x10^{-16}$ *
Duration of Diabetes (weeks)	11 (6, 18)	10 (6, 17.5)	0.43
Hospital Admission (%)	531 (75)	396 (71)	0.15
DKA (%)	303 (43)	223 (41)	0.40
Polyuria (%)	666 (95)	534 (97)	0.26
Weight Loss (%)	597 (85)	479 (88)	0.24
HbA1c (mmol/mol)	81 (57, 106)	87 (64, 110)	0.01
BMI, kg/m ²	23.3 (20.9, 26.2)	23.7 (21.5, 26.7)	0.02
Parent with Diabetes (%)	92 (13)	112 (20)	6x10 ⁻⁴ *
Other autoimmune condition (%)	39 (5)	71 (13)	5x10 ⁻⁶ *
T1D-GRS	0.275 (0.256, 0.293)	0.274 (0.253, 0.292)	0.58
HLA-DR3-DQ2 (%)	359 (50)	328 (59)	$3x10^{-3}$
HLA-DR4-DQ8 (%)	382 (54)	273 (49)	0.10
Number of positive autoantibodies			0.43
One (%)	179 (25)	148 (27)	
Two (%)	201 (28)	170 (31)	
Three (%)	331 (47)	239 (43)	
IA-2A (%)	454 (64)	345 (62)	0.48
IA-2A level (DK U/ml) [#]	255 (125, 340)	254 (95, 339)	0.59
ZnT8A (%)	409 (58)	303 (54)	0.27
ZnT8A level (AU/ml) [#]	36 (11, 78)	43 (13, 86)	0.13
· /	× <i>, ,</i> ,	~ / /	

 465
 Table 1: Comparison of clinical characteristics at diagnosis between high and low

466 GADA level groups for GADA positive type 1 diabetes cases. Bimodal GADA level

467 distribution was divided into two groups using the nadir between the two modes at 452 DK

468 U/ml. Values expressed as median (interquartile range) unless stated. [#]Only for people who

469 were positive for that antibody * indicates a p value lower than threshold the *P* value for

470 multiple comparisons (0.05/19 = 0.0026)

Characteristic	Low Level IA-2A	High Level IA-2A	P value
n (%)	285 (28)	749 (72)	
IA-2A level (DK U/ml)	27 (9, 71)	297 (239, 359)	
Female (%)	111 (39)	327 (44)	0.17
Age of Diagnosis (years)	22.4 (13.1, 33.5)	17.0 (11.9, 25.2)	$4x10^{-6}*$
Duration of Diabetes (weeks)	11.3 (5.9, 18.6)	11.5 (6.6, 18.6)	0.41
Hospital Admission (%)	207 (73)	605 (81)	$4x10^{-3}$
DKA (%)	123 (44)	323 (44)	0.97
Polyuria (%)	268 (95)	714 (97)	0.20
Weight Loss (%)	236 (84)	629 (86)	0.32
HbA1c (mmol/mol)	83 (58, 114)	76 (56, 101)	0.02
BMI	23.6 (21.3, 26.4)	23.2 (21.2, 25.9)	0.27
Parent with Diabetes (%)	45 (16)	101 (14)	0.35
Other autoimmune condition (%)	24 (8)	41 (5)	0.08
T1D-GRS	0.275 (0.254,	0.275 (0.258,	0.78
	0.294)	0.293)	
HLA-DR3-DQ2 (%)	157 (55)	327 (44)	9x10 ⁻⁴ *
HLA-DR4-DQ8 (%)	145 (51)	749 (68)	$5 \times 10^{-7} *$
Number of positive autoantibodies			1x10 ⁻⁹ *
One (%)	39 (14)	35 (5)	
Two (%)	127 (45)	263 (35)	
Three (%)	119 (42)	451 (60)	
GADA (%)	217 (76)	582 (78)	0.59
GADA level (DK U/ml)	374 (161, 671)	323 (114, 690)	0.10
ZnT8A (%)	148 (52)	583 (78)	$2x10^{-16}$ *
ZnT8A level (AU/ml)	26 (7.7, 55)	44 (16, 86)	$1 \times 10^{-5} *$
Table 2: Comparison of clinica			

472 Table 2: Comparison of clinical characteristics at diagnosis between high and lowIA-2A

473 level groups for positive IA-2A type 1 diabetes cases. Bimodal IA-2A level distribution

474 was divided into low and high level groups using the nadir between the mode at 130 DK

475 U/ml. [#] only for people who were positive for that antibody * indicates a *P* value lower than

threshold the *P* value for multiple comparisons (0.05/19 = 0.0026)

477 Figure Legends

Figure 1: Histograms with kernel density curves showing the distribution of islet autoantibody levels in patients with type 1 diabetes at diagnosis. A) Histogram of GADA

- 479 autoantibody levels in patients with type 1 diabetes at diagnosis. A) Histogram of GADA 480 level at diagnosis measured using radiobinding assay for type 1 diabetes cases who were
- 480 level at diagnosis measured using radiobinding assay for type 1 diabetes cases who were
- 481 positive for GADA (n=1,268). GADA level exhibits a bimodal distribution. The nadir value 482 of 452 DK U/ml between the two mode is highlighted with black dashed line and used to
- of 452 DK U/ml between the two mode is highlighted with black dashed line and used to defined high GADA level group (\geq 452 DK U/ml) and low level group (<452 DK U/ml). B)
- Histogram of IA-2A level at diagnosis measured using radiobinding assay for type 1 diabetes
- 484 Instogram of IA-2A level at diagnosis measured using radiobiliding assay for type 1 diabetes 485 cases who were positive for IA-2A (n=1,034). IA-2A level exhibits a bimodal distribution.
- The nadir value of 130 DK U/ml between the two mode is highlighted with black dashed line
- and used to defined high IA-2A level group (\geq 130 DK U/ml) and low level group (<130 DK
- U/ml). C) Histogram of ZnT8A levels at diagnosis measured using radiobinding assay for
- 489 type 1 diabetes cases who were positive for ZnT8 (n=906) show a right skewed distribution.
- 490 Median value of the distribution (35.4 AU/ml) is highlighted with black dashed lines and
- 491 used to define high level ZnT8A (\geq 35.4 AU/ml) and low level (<35.4 AU/ml) groups.

492 Figure 2: Box plot showing age of diagnosis of type 1 diabetes in high and low level

493 groups for GADA, IA-2A and ZnT8A. The nadir value between the two modes of GADA

level (452 DK U/mL) and IA-2A level (130 DK U/mL) distribution at diagnosis of type 1

diabetes who were positive for respective autoantibodies was used to define high and low

- level categories. There were 711/1,268 and 557/1,268 cases in low and high level GADA
- groups and 285/1,034 and 749/1,034 cases in low and high level IA-2A groups. The median
- 498 value of ZnT8A level (35.4 AU/ml) was used for defining low and high level groups (n=453
- 499 each). Median age of diagnosis was higher for the high level GADA group ($P=3x10^{-16}$),

lower for the higher level IA-2A ($P=4x10^{-6}$) and similar between ZnT8A level categories (P=0.07).



